Tesamorelin
Also known as: Egrifta
Tesamorelin is a prescription medication or prescription-only peptide topic. Use this page to understand what it is used for, what side effects to ask about, and how it fits into a clinician-guided plan.
Multiple Phase III trials supporting visceral fat reduction. FDA-approved indication gives it the strongest evidence base of any GH secretagogue.
What to know before you go deeper
Stabilized GHRH analog. More potent and longer-acting than sermorelin. Selectively reduces visceral adipose tissue with less effect on subcutaneous fat.
Approval status: Prescription. Read the details before assuming it fits your situation.
Visceral fat reduction, Body composition improvement, GH deficiency.
What evidence applies to my situation, what monitoring is needed, and what safer first steps should I try?
Why People Ask About Tesamorelin
- Visceral fat reduction
- Body composition improvement
- GH deficiency
Questions to Bring Up
FDA-approved prescription medication for a specific indication; use should follow the product label and prescriber guidance.
Dosing, sourcing, and suitability questions belong with a licensed clinician who can review your history, labs, medications, and goals.
Known Side Effects
- Injection site reactions
- Fluid retention
- Joint pain
- Glucose changes
Important Safety Notes
Prescription only
Contraindicated in active malignancy
Monitor glucose — can affect insulin sensitivity
Most expensive of the GHSs due to FDA approval pathway
What Is Approved?
FDA-approved for HIV-associated lipodystrophy. Widely prescribed off-label for visceral fat reduction and body composition.
Your feedback helps us improve the guide.